摘要
目的探究非那雄胺联合塞来昔布治疗慢性前列腺炎对巨噬细胞集落刺激因子(M-CSF)、单核细胞趋化蛋白-1(MCP-1)水平表达的影响。方法选取我院2020年5月-2023年3月收治的慢性前列腺炎患者218例作为本次研究对象。218例患者平均分为观察组、对照组各109例。观察疗效、症状评分、M-CSF、MCP-1水平。结果观察组治疗总有效率(93.58%)高于对照组(85.32%),差异显著,χ^(2)=3.937,P=0.047。治疗前两组的NIH-CPSI评分比较差异不显著(P>0.05),治疗后,观察组NIH-CPSI评分低于对照组,差异显著,P<0.05。治疗前两组的M-CSF、MCP-1水平比较差异不显著(t=0.521,P=0.603,t=1.084,P=0.280),治疗后,观察组M-CSF(168.73±53.24)pg/mL、MCP-1(3.42±0.85)ng/mL水平均低于对照组(205.44±49.71)pg/mL、(4.22±1.12)ng/mL,差异显著,P<0.05。结论非那雄胺联合塞来昔布用于治疗慢性前列腺炎效果良好,该治疗方案能够降低M-CSF、MCP-1水平,改善患者临床症状,提高生活质量。
Objective To investigate the effects of finasteride combined with celecoxib on the expression of macrophage colony-stimulating factor(M-CSF)and monocyte chemotactic protein-1(MCP-1)in the treatment of chronic prostatitis.Methods 218 patients with chronic prostatitis treated in our hospital from May 2020 to March 2023 were selected as the objects of this study.The 218 patients were divided into observation group and control group with 109 patients respectively.The therapeutic effect,symptom score,M-CSF,MCP-1 level were observed.Results The total effective rate of observation group(93.58%)was higher than that of control group(85.32%),the difference was significant,c2=3.937,P=0.047.There was no significant difference in NIH-CPSI score between the two groups before treatment(P>0.05).After treatment,the NIH-CPSI score of the observation group was lower than that of the control group,with significant difference(P<0.05).There were no significant differences in M-CSF and MCP-1 levels between the two groups before treatment(t=0.521,P=0.603,t=1.084,P=0.280).The M-CSF(168.73±53.24)pg/mL and MCP-1(3.42±0.85)ng/mL levels in the observation group were lower than those in the control group(205.44±49.71)pg/mL and(4.22±1.12)ng/mL,with significant differences(P<0.05).Conclusion Finasteride combined with celecoxib is effective in the treatment of chronic prostatitis,which can reduce M-CSF and MCP-1 levels,improve the clinical symptoms and improve the quality of life of patients.
作者
刘涛
方晓
黄金明
LIU Tao;FANG Xiao;HUANG Jin-ming(Department of Urology,the First Affiliated Hospital of Nanyang Medical College,Nanyang 473000,Henan Province,China)
出处
《罕少疾病杂志》
2024年第3期78-79,共2页
Journal of Rare and Uncommon Diseases
基金
河南省医学科技攻关计划联合共建项目(2021020984)。
